Anika Therapeutics (ANIK) Operating Leases (2019 - 2026)

Anika Therapeutics (ANIK) has 8 years of Operating Leases data on file, last reported at $23.8 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $23.8 million, up 0.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.8 million (up 0.98% YoY), and the FY2025 annual result was $24.2 million, up 0.76% from the prior year.
• Operating Leases fell to $23.8 million in Q1 2026 per ANIK's latest filing, from $24.2 million in the prior quarter.
• Over five years, Operating Leases peaked at $29.7 million in Q2 2022 and troughed at $18.8 million in Q1 2022.
• A 5-year average of $25.6 million and a median of $25.8 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2025: Operating Leases surged 50.27% in 2023, then decreased 10.56% in 2025.
• A 5-year view of Operating Leases shows it stood at $28.8 million in 2022, then slipped by 10.07% to $25.9 million in 2023, then slipped by 7.34% to $24.0 million in 2024, then rose by 0.76% to $24.2 million in 2025, then declined by 1.66% to $23.8 million in 2026.
• Business Quant data shows ANIK's Operating Leases at $23.8 million in Q1 2026, $24.2 million in Q4 2025, and $22.8 million in Q3 2025.